SU11248, A selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells-Reference-Cited by-同舟云学术

SU11248, A selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells

Published:2010-10 Issue:7 Volume:10 Page:703-711
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Young Emily,Miele Lucio,Tucker Kevan B.,Huang Min,Wells Jeremy,Gu Jian-Wei

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.4161/cbt.10.7.12904

Reference31 articles.

1. Transplacental Carcinogenesis by Stilbestrol

2. The biology of VEGF and its receptors

3. Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions

4. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer

5. Vascular Endothelial Growth Factor Mediates Intracrine Survival in Human Breast Carcinoma Cells through Internally Expressed VEGFR1/FLT1

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a synthetic taiwaniaquinoid with potent in vitro and in vivo antitumor activity against breast cancer cells;Biomedicine & Pharmacotherapy;2023-12

2. Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients;Frontiers in Oncology;2022-12-09

3. The Association Between the Risk of Breast Cancer and Epigallocatechin- 3-Gallate Intake: A Literature Review of a Potential Chemopreventive Agent;Current Medicinal Chemistry;2022-12

4. Escape from breast tumor dormancy: The convergence of obesity and menopause;Proceedings of the National Academy of Sciences;2022-10-03

5. Tumor Vascular Remodeling Affects Molecular Dissemination to Lymph Node and Systemic Leukocytes;Tissue Engineering Part A;2022-09-01